Dataset Information

Criminal behavioral data analysis for recidivation estimation in convicted offenders.

ABSTRACT: The act of continuing to commit crimes after being imprisoned for a first-time offence and freed is known as recidivism. The level of delinquent behavior in an individual character, that is closely associated to repeated recidivation, can be determined by assessing offenders behavioral features. The dataset includes 220 offenders, with a total of 204 participants whose data was used to create the desired dataset. The raw information was acquired using a questionnaire form that included personality traits, parental and family characteristics, socio-demographic characteristics, crime details, cumulative jail behavior elements, and the HCR-20 risk assessment technique. Behavior sample was gathered from several jails and correction facility in the Indian state of Jharkhand for the objective for initial relapse estimation from first convicts in the current study. The dataset can be used by criminologists, sociologists, psychologists, and academicians to determine an offender's pattern and psychological qualities. Specialists in detention centre undertook the felony evaluation.

SUBMITTER: Singh A

PROVIDER: S-EPMC9189775 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Criminal behavioral data analysis for recidivation estimation in convicted offenders.

Singh Aman A Mohapatra Subrajeet S Bhattacharya Madhumita M

Data in brief 20220529

The act of continuing to commit crimes after being imprisoned for a first-time offence and freed is known as recidivism. The level of delinquent behavior in an individual character, that is closely associated to repeated recidivation, can be determined by assessing offenders behavioral features. The dataset includes 220 offenders, with a total of 204 participants whose data was used to create the desired dataset. The raw information was acquired using a questionnaire form that included personali ...[more]

PMID: 35707247

Similar Datasets

Project description:BackgroundExtended-release naltrexone, a sustained-release monthly injectable formulation of the full mu-opioid receptor antagonist, is effective for the prevention of relapse to opioid dependence. Data supporting its effectiveness in U.S. criminal justice populations are limited.MethodsIn this five-site, open-label, randomized trial, we compared a 24-week course of extended-release naltrexone (Vivitrol) with usual treatment, consisting of brief counseling and referrals for community treatment programs, for the prevention of opioid relapse among adult criminal justice offenders (i.e., persons involved in the U.S. criminal justice system) who had a history of opioid dependence and a preference for opioid-free rather than opioid maintenance treatments and who were abstinent from opioids at the time of randomization. The primary outcome was the time to an opioid-relapse event, which was defined as 10 or more days of opioid use in a 28-day period as assessed by self-report or by testing of urine samples obtained every 2 weeks; a positive or missing sample was computed as 5 days of opioid use. Post-treatment follow-up occurred at weeks 27, 52, and 78.ResultsA total of 153 participants were assigned to extended-release naltrexone and 155 to usual treatment. During the 24-week treatment phase, participants assigned to extended-release naltrexone had a longer median time to relapse than did those assigned to usual treatment (10.5 vs. 5.0 weeks, P<0.001; hazard ratio, 0.49; 95% confidence interval [CI], 0.36 to 0.68), a lower rate of relapse (43% vs. 64% of participants, P<0.001; odds ratio, 0.43; 95% CI, 0.28 to 0.65), and a higher rate of opioid-negative urine samples (74% vs. 56%, P<0.001; odds ratio, 2.30; 95% CI, 1.48 to 3.54). At week 78 (approximately 1 year after the end of the treatment phase), rates of opioid-negative urine samples were equal (46% in each group, P=0.91). The rates of other prespecified secondary outcome measures--self-reported cocaine, alcohol, and intravenous drug use, unsafe sex, and reincarceration--were not significantly lower with extended-release naltrexone than with usual treatment. Over the total 78 weeks observed, there were no overdose events in the extended-release naltrexone group and seven in the usual-treatment group (P=0.02).ConclusionsIn this trial involving criminal justice offenders, extended-release naltrexone was associated with a rate of opioid relapse that was lower than that with usual treatment. Opioid-use prevention effects waned after treatment discontinuation. (Funded by the National Institute on Drug Abuse; ClinicalTrials.gov number, NCT00781898.).

Dataset Information

Criminal behavioral data analysis for recidivation estimation in convicted offenders.

Publications

Criminal behavioral data analysis for recidivation estimation in convicted offenders.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets